Genmab | GEN - Actif À Court Terme





Actif À Court Terme Changement Date
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
Almirall EUR 747.1M 33.12M 2026-06
Amarin USD 602.76M 23.26M 2026-06
Amgen USD 34.96B 3.49B 2026-06
argenx SE USD 8.07B 1.17B 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
Bayer EUR 33.64B 1.66B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Demant DKK 10.2B 130M 2026-06
Exelixis USD 1.25B 42.18M 2026-06
Fresenius Medical Care EUR 7.69B 418.66M 2026-06
Genmab DKK 2.8B 228M 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
GN Store Nord DKK 5.63B 783M 2026-06
GRIFOLS EUR 5.31B 51M 2026-06
Hikma Pharmaceutical USD 2.64B 86M 2025-12
Insmed USD 1.63B 20.75M 2026-06
Lakefront Biotherapeutics EUR 2.31B 751.38M 2026-06
Lonza CHF 8B 3.41B 2025-12
Merck EUR 13.77B 393M 2026-06
Novartis USD 27.35B 744M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 31.52B 1.36B 2026-06
UCB EUR 6.05B 733M 2025-12